Search

Your search keyword '"Skajaa, Nils"' showing total 34 results
Start Over Author "Skajaa, Nils"
34 results on '"Skajaa, Nils"'

4. Cohort Profile: Better Health in Late Life

Author

Sørensen, Henrik, additional, Christensen, Tina, additional, Bøtker, Hans Erik, additional, Christiansen, Christian, additional, Fuglsang, Cecilia, additional, Gribsholt, Sigrid, additional, Kristensen, Frederik, additional, Laugesen, Kristina, additional, Laursen, Anne, additional, Nørgaard, Mette, additional, Schmidt, Morten, additional, Skajaa, Nils, additional, Troelsen, Frederikke, additional, and Pedersen, Lars, additional

Published
2023
Full Text
View/download PDF

11. A Review of Major Danish Biobanks: Advantages and Possibilities of Health Research in Denmark

Author

Laugesen, Kristina, primary, Mengel-From, Jonas, additional, Christensen, Kaare, additional, Olsen, Jørn, additional, Hougaard, David M, additional, Boding, Lasse, additional, Olsen, Anja, additional, Erikstrup, Christian, additional, Hetland, Merete Lund, additional, Høgdall, Estrid, additional, Kjaergaard, Alisa D, additional, Sørensen, Erik, additional, Brügmann, Anja, additional, Petersen, Eva Rabing Brix, additional, Brandslund, Ivan, additional, Nordestgaard, Børge G, additional, Jensen, Gorm B, additional, Skajaa, Nils, additional, Troelsen, Frederikke Schønfeldt, additional, Fuglsang, Cecilia Hvitfeldt, additional, Svingel, Lise Skovgaard, additional, and Sørensen, Henrik T, additional

Published
2023
Full Text
View/download PDF

13. Cancer Diagnosis and Prognosis After Guillain–Barré Syndrome: A Population-Based Cohort Study

Author

Girma,Blean, Farkas,Dóra Körmendiné, Laugesen,Kristina, Skajaa,Nils, Henderson,Victor W, Boffetta,Paolo, and Sørensen,Henrik Toft

Subjects
Clinical Epidemiology
Abstract

Blean Girma,1 Dóra Körmendiné Farkas,2 Kristina Laugesen,2 Nils Skajaa,2 Victor W Henderson,2,3 Paolo Boffetta,4,5 Henrik Toft Sørensen2 1Department of Environmental Medicine and Public Health, Icahn School of Medicine, New York, NY, USA; 2Department of Clinical Epidemiology, Aarhus University Hospital and Aarhus University, Aarhus, Denmark; 3Departments of Epidemiology & Population Health and of Neurology & Neurological Sciences, Stanford University, Stanford, CA, USA; 4Stony Brook Cancer Center, Stony Brook University, Stony Brook, NY, USA; 5Department of Medical and Surgical Sciences, University of Bologna, Bologna, ItalyCorrespondence: Henrik Toft Sørensen, Department of Clinical Epidemiology, Aarhus University Hospital and Aarhus University, Olof Palmes Allé 43-45, Aarhus, 8200, Denmark, Tel +45 87 16 82 15, Email hts@clin.au.dkIntroduction: It is unclear whether Guillain–Barré syndrome (GBS) can be a marker of a paraneoplastic syndrome. We examined whether GBS is associated with cancer and whether the prognosis of GBS patients with cancer differs from that of other cancer patients.Materials and Methods: We conducted a population-based cohort study of patients diagnosed with GBS between 1978 and 2017 using Danish registry-data. Main outcome measures were cancer incidence and mortality after cancer diagnosis. We calculated absolute risks of a cancer diagnosis, treating death as competing risk, and standardized incidence ratios (SIRs) as measures of relative risk. We matched each GBS cancer patient with up to 10 cancer patients without a GBS diagnosis and examined the six-month survival after cancer diagnosis using Cox regression analysis.Results: We identified 7897 patients (58% male, median age 57 years) with GBS. During a median follow-up of 9.5 years, the one-year risk of cancer was 2.7% (95% confidence interval (CI), 2.4– 3.1). The SIR was increased throughout follow-up, but most noticeably during the first year after diagnosis (SIR: 3.35, 2.92– 3.83). SIRs were particularly elevated for hematologic cancers (SIR: 8.67, 6.49– 11.34), smoking-related cancers (SIR: 3.57, 2.81– 4.47), and cancers of neurological origin (SIR: 8.60, 5.01– 13.77). Lung cancer was the main contributor to the overall excess risk, which persisted after 36 months of follow-up (SIR: 1.17, 1.09– 1.25). The mortality rate ratio comparing patients diagnosed with any cancer within one year of their GBS diagnosis and matched GBS-free cancer cohort members was 1.56 (95% CI, 1.27– 1.90).Conclusion: GBS patients had a three-fold increased risk of cancer diagnosis in the first year of follow-up. The absolute cancer risk was almost 3.0%. A GBS diagnosis was an adverse prognostic marker for survival following cancer diagnosis. Clinicians should consider occult cancer in patients hospitalized with GBS.Keywords: Guillain–Barré syndrome, cancer, paraneoplastic syndrome, survival, risk, cohort

Published
2022

33. Cesarean delivery and risk of atopic dermatitis.

Author

Skajaa, Nils, Nissen, Thomas Nørrelykke, Birk, Nina Marie, Jeppesen, Dorthe Lisbeth, Thøstesen, Lisbeth Marianne, and Benn, Christine Stabell

Subjects
*CESAREAN section, *ATOPIC dermatitis, *ATOPY
Abstract

In two additional analyses, we compared the risk of atopic dermatitis between elective and emergency cesarean delivery, and between elective cesarean delivery and any other delivery. Atopic predisposition was slightly more prevalent in the cesarean delivery cohort than in the vaginal delivery cohort (72% vs 67%, I P i = .02) (Table). The risk of atopic dermatitis was similar between elective and emergency cesarean deliveries; compared with any other delivery types, elective cesarean delivery was associated with a slight increase in risk (Tables S3-S4). In the additional analyses comprising 88% of the children born by cesarean delivery, the risk of atopic dermatitis tended to be slightly increased for elective cesarean delivery compared with any other delivery type. [Extracted from the article]

Published
2020
Full Text
View/download PDF

34. Risk of mortality and recurrence after first-time stroke among patients with type 2 diabetes: A Danish nationwide cohort study.

Author

Kristensen FPB, Svane HML, Laugesen K, Al-Mashhadi SK, Christensen DH, Sørensen HT, and Skajaa N

Abstract

Introduction: The prognosis for stroke patients with type 2 diabetes mellitus (T2DM) remains poorly understood. We examined the risk of mortality and stroke recurrence in stroke patients with T2DM and stroke patients without diabetes., Patients and Methods: We conducted a population-based cohort study including all patients diagnosed with a first-time ischemic stroke ( n  = 131,594) or intracerebral hemorrhage (ICH, n  = 15,492) in Denmark, 2005-2021. Patients with T2DM were identified using hospital diagnosis codes and glucose-lowering drug prescriptions. We calculated risks, risk differences, and risk ratios, standardized by age, sex, and calendar year of stroke admission., Results: Following ischemic stroke, the 5-year standardized mortality was 46.1% for patients with T2DM and 35.4% for patients without diabetes (standardized risk difference: 10.7% [95% CI 9.9-11.6]; risk ratio: 1.3 [95% CI 1.3-1.3]). The 5-year risk of recurrence following ischemic stroke was 12.7% for patients with T2DM and 11.3% for those without diabetes (risk difference: 1.4% [95% CI 0.9-2.0]; risk ratio: 1.1 [95% CI 1.1-1.2]). Following ICH, the 5-year mortality was 62.8% for patients with T2DM and 53.0% for patients without diabetes (risk difference: 9.8% [95% CI 7.2-12.4)]; risk ratio: 1.2 [95% CI 1.1-1.2]). The 5-year risk of recurrence after ICH was 9.1% for patients with T2DM and 9.7% for patients without diabetes., Discussion and Conclusion: Stroke patients with T2DM were at increased risk of mortality. The risk of stroke recurrence was slightly higher for ischemic stroke patients with T2DM than patients without diabetes, while no difference was observed among ICH patients., Competing Interests: Declaration of conflicting interestsThe author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: DHC has received support from Novo Nordisk for attending the European Association for the Study of Diabetes (EASD) Annual Meeting 2023 in Hamburg. DHC is supported by a research grant from the Danish Diabetes and Endocrine Academy, which is funded by the Novo Nordisk Foundation, grant number NNF22SA0079901. NS reports receiving speaker honoraria from Pfizer outside the submitted work. N.S was affiliated with the Department of Clinical Epidemiology, Aarhus University and Aarhus University Hospital during the initiation of this study but is now an employee of Novo Nordisk A/S. Department of Clinical Epidemiology, Aarhus University, receives funding for other studies in the form of institutional research grants to (and administered by) Aarhus University. None of these studies has any relation to the present study. The other authors report no conflicts.

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results